Primary |
Product Used For Unknown Indication |
75.0% |
Intentional Self-injury |
12.5% |
Depression |
6.3% |
Renal Transplant |
6.3% |
|
Bradyphrenia |
25.0% |
Incorrect Dose Administered |
25.0% |
Intentional Self-injury |
25.0% |
Toxicity To Various Agents |
25.0% |
|
Secondary |
Product Used For Unknown Indication |
29.9% |
Suicide Attempt |
23.3% |
Bipolar Disorder |
13.2% |
Drug Use For Unknown Indication |
9.7% |
Self Injurious Behaviour |
6.1% |
Depression |
5.3% |
Intentional Self-injury |
4.0% |
Ill-defined Disorder |
1.5% |
Personality Disorder |
1.0% |
Hypothyroidism |
0.8% |
Intentional Overdose |
0.8% |
Anxiety |
0.6% |
Drug Abuse |
0.6% |
Hypertension |
0.6% |
Acute Psychosis |
0.5% |
Asthma |
0.5% |
Psychotic Disorder |
0.5% |
Bulimia Nervosa |
0.3% |
Dementia Alzheimer's Type |
0.3% |
Gastritis Prophylaxis |
0.3% |
|
Self Injurious Behaviour |
22.2% |
Sopor |
15.1% |
Sluggishness |
11.9% |
Tachycardia |
7.1% |
Toxicity To Various Agents |
5.6% |
Drug Abuse |
4.0% |
Overdose |
4.0% |
Vomiting |
4.0% |
Hypotension |
3.2% |
Multiple Drug Overdose Intentional |
3.2% |
Suicide Attempt |
3.2% |
Bradycardia |
2.4% |
Respiratory Failure |
2.4% |
Sinus Bradycardia |
2.4% |
Transaminases Increased |
2.4% |
Coma |
1.6% |
Gamma-glutamyltransferase Increased |
1.6% |
Loss Of Consciousness |
1.6% |
Paraesthesia |
1.6% |
Altered State Of Consciousness |
0.8% |
|
Concomitant |
Product Used For Unknown Indication |
26.4% |
Schizophrenia |
8.8% |
Pain |
8.3% |
Anxiety |
7.9% |
Drug Use For Unknown Indication |
7.9% |
Prophylaxis |
7.9% |
Psychotic Disorder |
5.1% |
Hypertension |
4.6% |
Bipolar Disorder |
2.8% |
Intentional Overdose |
2.8% |
Schizophrenia, Paranoid Type |
2.8% |
Diabetes Mellitus |
2.3% |
Benign Prostatic Hyperplasia |
1.9% |
Bone Pain |
1.9% |
Depression |
1.9% |
Urinary Tract Infection |
1.9% |
Affect Lability |
1.4% |
Extrapyramidal Disorder |
1.4% |
Hyperpyrexia |
1.4% |
Affective Disorder |
0.9% |
|
Delusion |
10.5% |
Agitation |
7.9% |
Syncope |
7.9% |
Acute Coronary Syndrome |
5.3% |
Drug Ineffective |
5.3% |
Hyperkalaemia |
5.3% |
Neutropenia |
5.3% |
Periorbital Haemorrhage |
5.3% |
Renal Pain |
5.3% |
Respiratory Failure |
5.3% |
Sopor |
5.3% |
Treatment Noncompliance |
5.3% |
Vertigo |
5.3% |
Weight Decreased |
5.3% |
Agranulocytosis |
2.6% |
Arterial Haemorrhage |
2.6% |
Atrial Fibrillation |
2.6% |
Blood Glucose Increased |
2.6% |
Bradycardia |
2.6% |
Choking Sensation |
2.6% |
|